SNDX - Latest News

Syndax Pharmaceuticals, Inc. (SNDX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.85B. Beta to the broader market is 0.41.

The article list below shows the most recent SNDX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent SNDX Headlines

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

globenewswire.com - May 12, 2026

– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data sh

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

globenewswire.com - May 6, 2026

NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative ca

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript

seekingalpha.com - Apr 30, 2026

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates

zacks.com - Apr 30, 2026

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0. 48 per share versus the Zacks Consensus Estimate of a loss of $0.

Syndax Reports First Quarter 2026 Financial Results and Provides Business Update

globenewswire.com - Apr 30, 2026

– Total revenue of $64. 9 million in 1Q26, a 224% year-over-year increase – – Revuforj ® (revumenib) net revenue of $48.

How News Affects SNDX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track SNDX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked SNDX news questions

What is the latest SNDX news headline?

The most recent SNDX headline (May 12, 2026) is "Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the SNDX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What SNDX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual SNDX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.